Cannabis Stock Research Reports: Medical Markets, Regulation and Cash

Cannabis sector news: the dated record

Regulatory, legal and company developments, newest first, each with its date and source; the federal hearing narrative is in the Federal File below. Proposals, effective rules and court steps are labeled as such: a bill or a draft rule is not law, and a stayed proceeding is not a decision.

October 2026

• October 30 — first federal registrations

  Federal / DOJ–DEA — more than 900 medical-marijuana dispensaries receive initial federal registrations

  The Justice Department announced on October 30, 2026 that DEA had begun issuing federal registrations for qualifying medical-marijuana dispensaries under the Attorney General’s April 23 medical Schedule III order. The initial group includes more than 900 dispensaries operating under qualifying state medical programs in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia. Each successful applicant must satisfy federal requirements and pass DEA’s pre-registration investigation; a state dispensary license alone is not a federal registration. DEA continues phased review of other dispensaries and of manufacturers and distributors, including additional facility, production-control and quota checks where applicable.

  Scope: this is an implemented, limited federal medical-marijuana registration program, not adult-use legalization and not a final ruling in the separate, broader Schedule III rescheduling case. Marijuana outside the medical order remains subject to Schedule I controls. No new IRS Section 280E implementation guidance is established by this announcement.

  U.S. Department of Justice — October 30 announcement, Release 26-1276

• October 30 — DEA operational guidance

  Federal / DEA — timely applicant trading rules clarified; supply-chain compliance expected by November 29

  DEA published guidance for licensed medical-marijuana dispensers, manufacturers and distributors whose complete federal registration application and fee were submitted from April 28 through June 26, 2026. While an eligible application is pending and its state license remains valid, an applicant can continue specified Schedule III medical activities under the transitional regulation, and can obtain or supply qualifying medical marijuana only through other eligible timely applicants or entities holding the appropriate DEA registration. Applications withdrawn or finally denied do not qualify. A transaction with an ineligible, unregistered supplier can put an application or registration at risk.

  DEA expects these applicants to establish compliant trading relationships and supply chains by November 29, 2026. Operators should verify counterparties’ state licenses and DEA registrations or timely-application confirmation/document control numbers, and keep due-diligence records. Previously acquired stock may continue to be used in otherwise authorized activity; DEA also describes a narrow, conditional testing-laboratory enforcement-discretion exception where registered testing is unavailable under specified conditions. November 29 is the agency’s stated compliance expectation in guidance that expressly disclaims independent force of law, not a newly enacted rescheduling date or a blanket exemption for unlicensed suppliers.

  DEA Diversion Control — Timely Applicant Information, October 30, 2026 (official PDF)

• October 30 — proposed regulation; public comments through December 14

  California / Department of Cannabis Control — regular A/M license-separation rulemaking opens

  On October 30, 2026, DCC formally noticed DCC-2026-04-R. Its proposal would establish an expedited route for existing combined medicinal/adult-use license holders to receive distinct Medicinal (M) and Adult-Use (A) licenses, potentially held by different legal entities if specified conditions are met. The pathway is intended to support applications for the separate federal DEA medical-cannabis registration program, but is not itself a DEA registration or a federal tax determination.

  Status: proposed regular rulemaking, not a newly adopted permanent rule. Comparable emergency DCC rules have already been in force since June 4 and are currently scheduled to expire December 2, 2026. Written comments on the regular proposal close December 14, with a public hearing scheduled December 15. The DCC identifies possible Section 280E benefits for appropriately DEA-registered medical activities; actual federal registration and the relevant tax rules remain separate requirements.

  California DCC — DCC-2026-04-R, October 30 notice and proposed text · DCC — existing emergency A/M rule

• October 29 — passed both houses; Governor’s signature pending

  New Jersey — S4635 hemp-beverage extension passes the Assembly 75–2 after Senate approval 37–0

  On October 29, 2026, the New Jersey Assembly substituted Senate bill S4635 for companion A5604 and passed it 75–2 (three not voting). The Senate had approved S4635 37–0 on October 22, following its October 15 committee advance. The measure has now cleared both chambers and awaits Governor Mikie Sherrill’s action. It is not yet enacted or effective.

  If signed, S4635 would replace the current November 13, 2026 state cutoff for specified qualifying intoxicating hemp-beverage sales with a federal compliance date no earlier than December 11, 2026, allowing later alignment if relevant federal deadlines change. Sales would remain limited to eligible Alcoholic Beverage Control (ABC) or Cannabis Regulatory Commission (CRC) licensees, with product, age, testing and other restrictions. The bill does not legalize all cannabinoid beverages or override separate federal restrictions on synthesized/non-natural cannabinoids. Until enacted, New Jersey CRC guidance still identifies November 13 as the sales cutoff. The separate enforcement proposal S4287 also remains a bill, not law.

  New Jersey Legislature — S4635, actions and roll calls · Official text of S4635 · New Jersey CRC — current law and November 13 cutoff · S4287 proposal

• October 29 — introduced in Congress; not enacted

  Federal / U.S. House — H.R. 10929 proposes a 50% additional duty on defined Chinese cannabinoid imports

  Representative Val Hoyle introduced the Protecting American Hemp Farmers Act (H.R. 10929) on October 29, 2026; it was referred to the House Ways and Means Committee. The bill would add a 50% tariff on designated cannabinoid/hemp-derived products originating in China, establish separate customs classifications for several cannabinoid categories and require testing of covered cannabinoid imports intended for human consumption. The additional duty would begin 90 days after enactment if the bill became law.

  Status and practical effect: newly introduced legislative proposal only; no congressional passage, presidential signature or new tariff is in force. The possible consequences for importers, processors, sourcing costs and testing depend on future votes, final text and implementation. The proposal does not change existing marijuana scheduling or Section 280E treatment.

  U.S. Government Publishing Office — H.R. 10929 as introduced, October 29 (PDF)

• October 28 — signed into law

  New York — S10643 signed as Chapter 369: labor-peace agreements no longer a mandatory cannabis-licensing condition

  Governor Kathy Hochul signed Senate Bill S10643 (Assembly companion A11562) on October 28, 2026. Sections 1–7 took effect immediately, repealing statutory requirements that cannabis license applicants and licensees enter into or maintain labor-peace agreements as a condition of licensure, registration or renewal. This does not bar voluntary agreements, invalidate existing contracts or repeal general labor laws. For regulated operators, it removes a specific mandatory labor-agreement compliance condition, not licensing or other regulatory obligations.

  The signed law also contains new ownership and workforce-pay disclosures and a Cannabis Industry Wage Board, with those provisions scheduled to take effect on January 31, 2027. The governor’s approval memorandum refers to a negotiated plan for subsequent chapter amendments to remove the wage-board and disclosure provisions, but these amendments still require legislative passage: they have not been enacted as of October 29. No cannabis-specific wage increase takes effect from the October 28 signing. The remaining 2027 obligations should not be described as already canceled.

  New York State Senate — S10643, October 28 signature and Chapter 369 · New York State Assembly companion A11562

• October 28 — emergency law reaches scheduled expiration

  Washington, D.C. — emergency medical-cannabis licensing rules expire; temporary successor awaits congressional review

  D.C. Act 26-391, signed July 30, 2026, reaches its scheduled October 28 end after a 90-day emergency period, as confirmed by the Alcoholic Beverage and Cannabis Administration (ABCA). It allowed certain medical-cannabis conditional licenses to run for up to three years, accepted a zoning certificate in place of a certificate of occupancy in specified permanent-license applications, clarified location restrictions, and expanded enforcement against unlicensed sellers. Mayor Muriel Bowser signed the corresponding temporary measure, Bill 26-760 / Act 26-448, on October 21; the Council-approved measure was transmitted for congressional review. The temporary act is NOT operative merely because it was signed: a 30-legislative-day congressional review applies, and its effective date has not been confirmed. Without a separately effective bridge, continuity of the emergency-only provisions after October 28 cannot be assumed. Other existing licensing requirements may continue independently. This is a licensing and enforcement transition, not legalization of recreational cannabis sales.

  D.C. ABCA — emergency act and October 28 sunset · D.C. Law Library — Act 26-391 · D.C. Council — temporary Bill 26-760

• October 26 — final rules published; effective November 5

  South Dakota — Department of Health finalizes medical-cannabis rule amendments

  The official South Dakota Register of October 26 lists finalized amendments across medical-cannabis Administrative Rules Article 44:90. After a September 23 hearing, the Department of Health filed the final rules with the Secretary of State on October 16; the published effective date is November 5, 2026. The amendments concern multiple operational and regulatory provisions of the medical-cannabis program, potentially affecting compliance for licensed businesses, laboratories and other program participants. This is final rulemaking with a future effective date, not a pending bill. The Register identifies the affected rule numbers but does not reproduce the full adopted text: specific effects of individual amendments must be checked against the final rule text rather than inferred from earlier drafts.

  South Dakota Legislature — Register, October 26, p. 56 · South Dakota Department of Health — rulemaking docket 970

• October 26–30 — application window open

  Georgia — eligible producers can apply for additional medical-cannabis dispensary licenses

  The Georgia Access to Medical Cannabis Commission opened its scheduled regular dispensing-license application window on October 26, 2026; it closes October 30. The schedule was announced in the Commission’s September 30 meeting. Under Rule 351-3-.02, only existing Class 1 and Class 2 medical-cannabis production licensees may apply, with a separate application for each proposed location. The state’s medical-cannabis patient registry passed the 55,000-patient threshold in September, permitting eligible producers to seek a ninth dispensing site under the statutory expansion formula.

  This is an operational licensing window, not the award of a license or the opening of a dispensary. All applications remain subject to Commission review and approval. The measure does not authorize adult-use marijuana sales.

  Georgia Commission — September 30 meeting and official summary · Georgia Commission — dispensing-license application

• October 23 — updated agency guidance

  Missouri: HB 2641 guidance addresses privacy, hemp licensing and conditional THC-beverage rules

  On October 23 the Missouri Division of Cannabis Regulation updated its official guidance for HB 2641, signed April 23, 2026, with key provisions effective November 12. Licensed dispensaries cannot create or retain consumer-identifying records without affirmative written consent, with a $500 fine per violation. State agencies cannot disclose medical-marijuana patient information to federal authorities without a subpoena or court order. Mandatory patient/caregiver records and seed-to-sale tracking requirements remain.

  Covered intoxicating hemp-derived cannabinoid products enter Missouri’s licensed marijuana framework. The agency currently identifies a conditional exception until December 11, 2026 for beverages containing naturally occurring, non-synthesized cannabinoids, restricted to customers age 21 and older; subsequent federal action could change the cutoff. Licensees may source qualifying low-THC hemp products (up to 0.3% total THC or, where applicable, no more than 0.4 mg total THC) outside the marijuana license chain; chemically converted or synthetic cannabinoids remain prohibited for licensees. This is implementation guidance for an enacted state law, not a new federal rescheduling decision.

  Missouri DCR — guidance updated October 23 · Missouri Governor — HB 2641 signed April 23

• October 22 — administrative order

  DEA: GAO report admitted; hearing not reopened; briefs due October 29 and November 5

  Chief Administrative Law Judge Derek C. Julius (DEA Docket 1362 / Hearing Docket 26-96) admitted the September 23 GAO report as Finn Exhibit 126 but denied reopening the completed evidentiary hearing for further evidence or testimony. He permitted limited written arguments about the weight of the GAO report and its possible bearing on the proposed broad Schedule III change: supplemental briefs due October 29, 2026 and optional replies due November 5, 2026, each capped at ten double-spaced pages. The existing stay remains effective until briefing closes, when it expires automatically under the order.

  This is a procedural ruling, not a recommended merits decision, a final general rescheduling rule, or newly effective Section 280E tax guidance. The separate federal medical-marijuana order must not be confused with the broader pending case.

  DEA — October 22 official order and NPRM docket

• October 22 — draft, not effective regulation

  Massachusetts CCC reviews proposed cannabis testing and independent-laboratory rules

  The Cannabis Control Commission began reviewing draft testing regulations under 935 CMR to implement Chapter 65 of the Acts of 2026. The proposal addresses the activities and quality systems of independent testing labs, sampling and sample retention, contaminant limits, and remediation or retesting of failed batches. Further discussion is planned for November 12; formal public comment is anticipated in early 2027. No new binding testing obligations take effect as a result of the October 22 discussion.

  Massachusetts CCC — official October 22 announcement and draft

• October 21 — enacted law effective; taxes begin 2027

  Delaware: HB 373 THC-infused beverage authorization takes effect

  House Bill 373 was signed July 23, 2026 and its primary authorization and licensing provisions took effect October 21. Licensed liquor package stores, marijuana retailers and authorized microbreweries may sell eligible non-alcoholic delta-9 THC beverages for off-premises consumption, subject to the appropriate endorsement or permit, testing, labeling, packaging, age-21 and distribution requirements. The legal potency ceilings are 10 mg per single-serving container, 60 mg per multipack and 170 mg per 750 mL bottle. The drinks cannot contain alcohol.

  Delaware’s Office of the Marijuana Commissioner lists an excise tax of $0.50 per single-serving container or $8.50 per 750 mL bottle from February 1, 2027. The state law does not authorize unlicensed general retail sales or change federal cannabis scheduling.

  Delaware OMC — HB 373 beverage program · Delaware Code — October 21 effective provisions

• October 21 — variance effective November 12

  Missouri clarifies acquisition of outside-state cannabis genetics under 0.3% total THC

  Missouri’s Division of Cannabis Regulation issued a variance aligning 19 CSR 100-1.160(1)(A)2 with section 195.900, RSMo, effective November 12, 2026. Licensees may obtain genetic plant material, tissue culture or pollen from outside Missouri’s licensed cultivation chain only if it contains no more than 0.3% total THC. Plants taller than two inches are presumed marijuana unless testing shows otherwise; seeds from plants above that threshold remain restricted even when the seed itself has low THC. Marijuana sold in the state must still originate in cultivation inside a Missouri-licensed facility. Received genetics must enter track-and-trace records that day; improper inversion can trigger sanctions or recalls.

  Missouri DHSS / DCR — October 21 compliance guidance

• October 19 — oversight audit, not a law

  Colorado audit 2553P identifies gaps in cannabis testing, inspections and health alerts

  The Colorado Office of the State Auditor released its Marijuana Consumer Safety performance audit, report 2553P. Findings cover limited state reference-lab capacity, uneven facility inspections and private-lab oversight, and delays or reach gaps in consumer health advisories. The reviewed agencies accepted 14 recommendations, with implementation work planned across subsequent years. The audit does not itself introduce any immediately binding new testing rule and does not demonstrate widespread contamination of products sold in Colorado.

  Colorado General Assembly / State Auditor — report 2553P

• October 14

  Illinois — hemp-derived products above 0.4 mg total THC per container become cannabis on November 12

  Illinois Department of Revenue Bulletin FY 2027-04 implements Public Act 104-0463. Beginning November 12, 2026, consumable or topical hemp products containing more than 0.4 mg of total THC per container — including THCa and specified cannabinoids with similar effects — no longer meet the state definition of hemp and are treated as cannabis. They may be grown only by Illinois Department of Agriculture cannabis cultivators and sold only through licensed cannabis dispensaries under the Cannabis Regulation and Tax Act. Compliant final consumer hemp cannabinoid products remain lawful but are subject to testing, labeling and child-resistant packaging requirements.

  Illinois says enforcement begins November 12 regardless of the later federal enforcement timeline. Businesses holding noncompliant inventory face potential seizure and civil or criminal consequences if they possess or sell newly classified cannabis without the required license.

  October 21 licensing guidance: Illinois Department of Agriculture now specifies a Hemp Product Manufacturer license for facilities extracting or processing hemp cannabinoids or making intermediate/final cannabinoid products. Applicants seeking a provisional license for the November 12 start should apply by 4 p.m. on November 9. A full license requires a complete application, an onsite inspection and payment of the $5,000 fee when the license is ready. Selling, storing, transporting or distributing already-packaged compliant hemp consumer products does not, by itself, require this manufacturer license. Existing Industrial Hemp Processor registrations terminate November 12 and processors requiring authorization must apply under the new Act. These requirements concern hemp products within the state definition, not authorization to sell newly classified cannabis above 0.4 mg per container.

  Illinois Department of Revenue — FY 2027-04 · Illinois General Assembly — Public Act 104-0463 · Illinois IDOA — manufacturer licensing and November 9 application guidance

• October 14

  Federal — ALJ grants reply and orders Government response by October 21

  Administrative Law Judge Derek C. Julius granted leave to file a reply concerning admission of the September 23 GAO report and deferred ruling on whether that report enters the record. The order also directs the Government to respond by October 21, 2026 to the motion seeking to reopen the hearing for additional evidence and testimony. The broader Schedule III proceeding remains stayed; the October 21 deadline is procedural, not a rescheduling decision date.

  DEA — NPRM 2026 docket and October 14 order

• October 9 — newly published filing

  Federal — DEA files response on the GAO report in the Schedule III proceeding

  In DEA Docket No. 1362 / Hearing Docket No. 26-96, the Government filed a response addressing the September 23 GAO report that triggered the September 29 stay. DEA argues that the report’s procedural-recordkeeping criticisms do not establish flaws in the scientific findings underlying the proposed move to Schedule III, opposes additional briefing over the GAO report, and leaves admissibility of the report to the Administrative Law Judge. This filing does not itself lift the stay, issue a recommended decision, or finalize rescheduling.

  DEA — marijuana rescheduling regulatory actions

• October 12

  Minnesota publishes required medical-product list

  OCM published guidance GM-2026-08 on October 12. Medical-endorsed manufacturers must produce high-medical-need products; medical-endorsed retail locations must stock the specified types from January 1, 2027. The list covers CBD-only, high-CBD, balanced THC/CBD and high-THC formulations, with requirements varying by delivery method. Retailers must carry at least one of the listed high-THC types. The listed types currently have no adult-use approval.

  Minnesota OCM: GM-2026-08 · OCM: retail start date

• October 12

  Oklahoma clarifies November 1 packaging transition

  OMMA clarified HB 4454 on October 12: products produced, processed, packaged or transferred to dispensaries from November 1 must meet the new requirements. Transfers of noncompliant products are prohibited from that date. Dispensaries may retain, display and sell inventory compliant with the previous labeling rules. Enforcement begins November 1, 2026.

  Oklahoma OMMA: HB 4454 clarification

• October 9

  Massachusetts: cultivation moratorium extended; license-extension conditions updated

  The October 9 bulletin confirms the October 8 vote: the pause on new adult-use cultivator applications and microbusiness applications without majority equity ownership continues through June 30, 2027. Microbusiness applicants majority-owned by eligible SEP participants or EEAs are exempt.

  A separate bulletin allows HCA-related license extensions of up to 365 days. New extensions from October 8 require good standing with the Department of Revenue, all required tax returns filed and a prorated fee. Requests must precede expiration; the Commission directs filing at least 14 days ahead. No additional HCA-related extensions will be granted after November 9, 2027; earlier extensions retain their terms until expiry.

  CCC: cultivation moratorium · CCC: license extensions

• October 9

  Washington — medical-cannabis certification rulemaking formally opened

  The Washington State Liquor and Cannabis Board filed CR-101 preproposal WSR 26-21-011 on October 9, formally opening rulemaking on Medical Cannabis Certification after accepting the underlying petition on October 7. The project is still at the preproposal stage: no final rule, certificate or effective date exists yet. The state process may create a formal way for licensed operators to document medical-cannabis activities, but it does not by itself guarantee federal DEA registration, banking access or Section 280E relief.

  Washington LCB — current rulemaking activity

• October 8

  Tilray: revenue grows, cannabis sales and adjusted EBITDA decline

  For Q1 FY2027 ended August 31, Tilray reported US$257.1 million revenue (+23% year over year), including US$56.1 million cannabis revenue versus US$64.5 million a year earlier. Net loss was US$40.0 million; adjusted EBITDA (non-GAAP) fell to US$9.2 million from US$10.2 million. FY2027 adjusted EBITDA guidance remains US$68–75 million. The results replace the previously scheduled earnings event.

  Tilray: October 8 results

• October 7 — portal verified

  DEA portal lists dedicated medical-marijuana Form 225 categories

  The DEA’s official new-registration portal now lists Medical Marijuana Manufacturer, Medical Marijuana Distributor and Medical Marijuana Analytical Lab under Form 225, alongside the separate medical-dispensary category under Form 224. This is an operational development for the medical supply chain; the portal’s availability does not establish that an applicant has received a registration. October 7 is our verification date, not a confirmed launch date. It does not resolve the broader rescheduling proceeding or establish new IRS guidance on Section 280E.

  DEA: new-registration portal · DEA registration information

• October 5–6

  Curaleaf raises its Aurora offer and extends it to December 4

  Curaleaf lifted the cash portion to US$1.00 and the exchange ratio to 0.4013 Curaleaf share per Aurora share, raised the cap to US$6.00 and moved expiry to 11:59 p.m. MT on December 4, 2026. It is an amended unsolicited offer, not an agreed deal.

  Curaleaf 8-K, October 6 · Curaleaf announcement (SEC exhibit)

• October 5

  Ohio — packaging, potency and quantity limits take effect

  Rule 1301:18-4-06 caps THC at 90%, flower at one ounce per package, vapes and other concentrates at 2 g per device or container, adult-use edibles at 10 mg per serving and 100 mg per package, and adult-use beverages at 10 mg per container.

  Ohio Admin. Code 1301:18-4-06

• October 5

  Ohio — new limits on non-cannabis ingredients

  Rule 1301:18-6-07 bans nicotine, melatonin, alcoholic beverages, dietary supplements and vitamins in cannabis products, allows caffeine only in narrow approved cases, and bars MCT oil, squalene, squalane, vitamin E acetate and propylene glycol from smoked or vaped products.

  Ohio Admin. Code 1301:18-6-07

• October 5

  Ohio — every cannabis ad now needs prior written approval

  Rule 1301:18-4-22 requires written approval from the Division of Cannabis Control before any ad runs, bans billboards, broadcast, transit and stadium advertising and prize-based promotions such as contests and raffles, and requires age affirmation on licensee websites.

  Ohio Admin. Code 1301:18-4-22

• October 5

  New Jersey — notice of enforcement action against Magic Garden Botanicals

  The official slides of the Cannabis Regulatory Commission’s October 5, 2026 special meeting list matter INV-132-2026, a notice of enforcement action against Magic Garden Botanicals LLC (Cultivator License #C000146). The slides describe the alleged violations as unapproved and unsecured outdoor cultivation on the licensed premises without Commission approval and failure to ensure that plants were properly tracked in Metrc; the item is presented for a Commission vote. As of October 7 the Commission’s resolutions page, which lists 2026 resolutions only through August 6, shows no corresponding resolution, so the outcome and any penalty are not confirmed by an official document.

  NJ-CRC — October 5 meeting slides · NJ-CRC — resolutions

• October 1

  Connecticut — flat 10.75% adult-use cannabis tax

  A 10.75% tax on gross receipts replaces the THC-based tax; with the 6.35% sales tax and 3% municipal tax, a $22 sale totals $26.43. The Social Equity and Innovation Account share rises from 65% to 70% for fiscal 2027–2028.

  Connecticut DRS — cannabis tax · DRS — 2026 tax developments

• October 1

  Connecticut — out-of-state medical patients can now buy

  Registered patients and caregivers from other states may buy up to 5 ounces a month at dispensary facilities and hybrid retailers with their home credential and photo ID; home grow is not allowed, and sales are reported in the state prescription-monitoring system.

  Connecticut DCP — out-of-state patients · DCP — out-of-state patient FAQs

• October 1

  California — new pesticide-testing thresholds

  The DCC rule DCC-2025-03-R is in force: Table 1 action levels apply until April 1, 2028, when new Table 2 action levels and quantitation limits take over. It is separate from the AB 1965 testing law.

  California DCC — DCC-2025-03-R

• October 1

  Maryland — medical-cannabis protection for fire and rescue staff

  Chapter 183 (SB 439) bars discipline of firefighters, EMTs, cardiac rescue technicians and paramedics for holding a valid medical certification or testing positive while certified; employers can still ban on-duty use or impairment.

  Maryland General Assembly — SB 439

• October 1

  Michigan — Muha Meds Ypsilanti license revoked

  The Cannabis Regulatory Agency revoked the adult-use retailer license of Budbridge LLC and fined it $251,250 for split transactions that bypassed purchase limits, plus ID, tracking and security violations.

  Michigan CRA — final order

• October 1

  Connecticut — broad October 1 rule package

  New rules on retesting and remediation, 60-day disposal of failed batches, potency caps (flower up to 35% THC, many manufactured products up to 70%, several concentrate categories without a ceiling), 30-day credit limits, single-employee transport under new security rules, wider adult-use access to some medical-only product forms with a 14-day medical priority, 24-hour retention of age-verification data and THC beverages.

  Connecticut DCP — notices · DCP — potency thresholds

• October 1

  New York — provisional retail licenses extended to 2028

  Resolution 2026-77 moves the provisional-license deadline for CAURD and adult-use retailers from December 31, 2026 to December 31, 2028, including qualifying provisional licenses issued through December 31, 2027.

  New York OCM — Resolution 2026-77

• October 1

  New York — capped nursery-license window from November 5

  Resolution 2026-76 opens a nursery-license application period on November 5, 2026 that closes after the first 50 submissions.

  New York OCM — Resolution 2026-76

• October 1

  New York — Gotham Buds penalty on sole-control rules

  Resolution 2026-78 imposes a $35,000 penalty and gives the licensee 90 days to file a revised operating agreement, with escalating penalties and possible suspension if it does not comply.

  New York OCM — Resolution 2026-78

• October 1

  Missouri — testing guidance for ingestible RSO and FECO

  These products remain concentrates subject to inhalation testing thresholds; ingestion-only products that fail them but stay below infused-product failure limits may request a variance, which is not automatic and requires ingestion-only instructions.

  Missouri DCR — guidance

• October 1

  Canada — technical amendments effective October 1

  Health Canada aligned certain Cannabis Regulations provisions with the new Controlled Substances Regulations, a technical compliance change.

  Health Canada — updates

Late September 2026

• September 30

  Missouri — emergency agent-card rule in force; licensing amendments proposed

  Proposed amendments to 19 CSR 100-1.070 and 1.100 are open for comment November 2–December 2, 2026; a separate emergency amendment on agent-card background checks took effect September 30.

  Missouri DCR — rule status

• September 14–30

  Companies — Trulieve, Cronos, Tilray, Canopy, Organigram, Aurora

  Trulieve joined the S&P Total Market and Completion indices; Cronos held its first Investor Day on September 24; Tilray released fiscal Q1 2027 results on October 8; see the latest entry above; Canopy’s September 25 meeting was adjourned for lack of quorum; at the reconvened meeting on October 23 shareholders approved a share consolidation of one new share for every five to fifteen existing shares, with the ratio left to the board; Organigram held its investor session on September 30; Curaleaf (September 14) and Aurora (September 23) filed applications with the Alberta Securities Commission over Aurora’s ATM share issuances and Curaleaf’s bid circular.

  Trulieve — index inclusion · Cronos — Investor Day · Tilray — results date · Curaleaf notice of variation (ASC application)

• September 29

  Federal — DEA stays the broader rescheduling hearing

  The Chief ALJ paused this general case on September 29. On October 22, he admitted the GAO report, denied reopening the evidentiary hearing and set supplemental briefing through November 5; the stay ends when briefing closes. This procedural step does not decide whether marijuana generally moves to Schedule III. The April medical order is a separate track.

  DEA — rescheduling actions · Stay and Briefing Order (PDF)

• September 29

  Michigan — 20 grower licenses revoked and a $2 million fine

  GP Holdings LLC (Millie Montana Industries) lost 20 medical Class C grower licenses and was fined $2 million after an administrative law judge recommended liability for all 35 alleged violations, including flower packages that contained no THC.

  Michigan CRA — announcement

• September 29

  IRS — Section 280E enters the priority guidance plan

  The 2026–2027 Treasury/IRS plan lists future 280E guidance as a work priority with no deadline; no implementation guidance has been issued, and Bulletin 2026-41 contains none.

  Treasury/IRS — priority plan · IRS — Bulletin 2026-41

• September 29

  Pennsylvania — Ryan’s Law clears committee, not enacted

  SB 1035, on compassionate medical access for terminally ill patients in health-care facilities, passed the Senate Law & Justice Committee 11-0; it has not passed the full Senate.

  Pennsylvania General Assembly — SB 1035

• September 27

  California — AB 1965 and AB 2250 signed

  AB 1965 adds off-the-shelf testing, certificates of analysis on request and laboratory performance testing; AB 2250 clarifies cannabinoid enforcement and excludes qualifying CBN isolate from “cannabis concentrate” from January 1, 2028.

  AB 1965 · AB 2250

• September 26

  Montana — third-party and operational-control rules in force

  Licensees must disclose covered third-party arrangements before work begins and identify every person with day-to-day operational control and document their Montana residency, updating the state within 30 days of a change.

  Montana DOR — third-party relationships · Montana DOR — operational control

• September 26

  Canada — Health Canada proposes simpler tracking reports

  A Canada Gazette I proposal would cut inventory classes from 14 to seven and repeal federal tracking reports for provincial bodies, distributors and retailers; comments are due November 10, 2026. Federal licence-holder changes would apply from January 1, 2028.

  Canada Gazette — proposed order

• September 25

  Massachusetts — discount advertising still restricted

  A Commission bulletin confirms that adult-use websites and menus may not advertise sales, discounts or promotions; a broader regulatory overhaul is heading to draft votes in December.

  CCC — advertising bulletin · CCC — regulatory overhaul

• September 18–25

  North Carolina and Pennsylvania — policy work, no market opening

  North Carolina’s advisory council published draft licensing recommendations, and Pennsylvania’s Senate Democratic Policy Committee held an adult-use hearing; neither creates a legal market.

  NCDHHS — advisory council · Pennsylvania Senate — policy hearings

• Late September

  Maryland — draft rule amendments, not yet effective

  Draft changes to COMAR 14.17 cover conditional licenses, ownership transfers, the micro-dispensary staff cap, advertising and labeling; the informal-feedback deadline was October 7 and a formal comment period would follow.

  Maryland Cannabis Administration — draft regulations

• September 23

  Federal — GAO finds gaps in DEA and FDA scheduling procedures

  The GAO recommended formal scheduling procedures and the agencies agreed; the report does not decide marijuana’s schedule.

  GAO-26-108623

Early and mid-September 2026

• September 16

  Federal — CLAIM Act reintroduced

  The bill would shield insurers serving state-legal cannabis businesses from certain federal liability; it is a proposal, not law.

  U.S. House — announcement

• September 8–16

  Companies — Aurora, Tilray and Cronos updates

  Aurora reaffirmed expected sequential growth for fiscal Q2 2027; Tilray issued 2,841,650 shares in exchange for US$12 million of notes due June 2027; Cronos extended the CanAdelaar long-stop date to October 15.

  Tilray filing · Cronos 8-K · Aurora release (SEC)

• September 15

  Supreme Court — residency-preference petition docketed

  Peridot Tree’s petition (No. 26-343) challenges in-state preferences in cannabis licensing; a response is due October 15 and the Court has not agreed to hear the case.

  Supreme Court docket

• July 29 / September 15

  Germany — flower out of statutory reimbursement; access curbs only proposed

  Since July 29 cannabis flower is no longer reimbursed by statutory health insurance, while extracts and specified medicines remain covered; proposed doctor-contact and mail-order limits are not yet law.

  German Health Ministry · SGB V §31

• Mid-September

  Florida — 22 new initial medical treatment-center licenses

  The state listed licenses MMTC-2026-0029 to 0050; each still needs cultivation, processing and dispensing approvals before selling, and the related application rule is only proposed.

  Florida OMMU — MMTC list · OMMU — notices

• September 9–14

  Netherlands and France — evidence and transition, not a market opening

  The Dutch WODC follow-up found no clear effects yet from the regulated-supply experiment; France keeps trial patients in a transition until after the forthcoming HAS opinion.

  WODC · French government

• September 14

  Maryland — final cannabis regulations effective September 14

  A final package on licensing, operations, products and packaging, including sublingual pouches, took effect September 14.

  Maryland Register — final action

• September 11; amended October 8

  Rhode Island — December 11 hemp limit and regulated quarantine option

  Amended Cannabis Office Bulletin 2026-7 addresses the federal 0.4 mg total-THC-per-container limit expected December 11, subject to further federal change. Products obtained lawfully before that deadline which exceed the new limit may remain in a designated quarantine area at the licensed facility. They cannot be further processed, moved, distributed or sold without explicit authorization. Operators must report quarantined inventory by December 4; products cannot be added to or removed from quarantine after December 11. Quarantine is not a sales extension, and the agency does not permit simply moving over-limit hemp products into licensed cannabis retail through an external transfer request.

  Rhode Island CCC — amended Bulletin 2026-7 (October 8)

• September 4–11

  Nebraska — medical-cannabis laws survive two challenges

  The Supreme Court affirmed the ruling in Kuehn v. Evnen and dismissed Kuehn v. Pillen for lack of standing, without prejudice; implementation continues.

  Kuehn v. Evnen · Kuehn v. Pillen

• September 10

  Illinois — 37 dispensaries licensed to serve medical patients

  Existing adult-use dispensaries received medical licenses under the SB 3222 opt-in, the largest expansion of medical access in about a decade.

  Illinois Governor — announcement

• September 9

  Federal — appeals court declines to stay the April medical order

  The D.C. Circuit denied a stay of the order moving FDA-approved and state-licensed medical marijuana products; the merits challenge continues.

  DOJ — scope of the medical order · D.C. Circuit docket

• September 9

  Virginia — draft retail-market rules

  The Cannabis Control Authority released draft retail regulations; the official timeline targets retail sales from July 1, 2027.

  Virginia CCA — retail timeline

• September 8

  Federal — GAO: cannabis banking access remains difficult

  GAO-26-107498, dated August 7 and released September 8, documents continuing barriers to accounts, loans and payments for state-legal cannabis businesses; it does not change banking law.

  GAO-26-107498

• September 2–8

  Companies — Aurora and Curaleaf set out their positions on the bid

  Aurora’s board recommended that shareholders reject Curaleaf’s offer on September 2; Curaleaf replied the same day and issued a fact sheet on September 8. These are the parties’ own positions.

  Aurora — SEC · Curaleaf — September 2 · Curaleaf — September 8

• September 4

  Ohio — injunction limits SB 56 hemp enforcement for plaintiffs

  A federal court protected the named plaintiffs from enforcement of SB 56’s amended hemp definition while their products remain federally lawful; SB 56 is not struck down statewide.

  Court order, Doc. 50

• September 3

  Connecticut — medical sales without a pharmacist on site

  Trained registered employees at hybrid retailers and dispensary facilities may complete medical sales without a pharmacist physically present, subject to training, audit and pharmacist-availability requirements.

  Connecticut DCP — notices

• September 2

  Federal — hemp deadline partly extended into law

  H.R. 6500, signed September 2, postpones most federal hemp restrictions from November 12 to December 11, 2026; limits on cannabinoids the plant cannot naturally produce keep the November 12 date.

  White House · Text, Section 2019

Earlier context still relevant

• August 31

  California — AB 2249 on youth-appealing marketing

  The law tightens packaging, labeling and advertising rules that appeal to children; most changes become operative in 2028.

  Governor of California

• June 24–25

  Federal — SAFE Banking Act introduced

  S.4942 and H.R.9471 would give banks protections for serving state-legal cannabis businesses; both are proposals, not law.

  Senate bill · House bill

Company-specific detail is in the individual stock hubs listed in the directory at the top of this page.

Scope of the historical discussion below: conditional references to a Schedule III move concern broader rescheduling and its possible extension beyond the medical categories already covered by the April order. Company-specific tax treatment is not established by a sector headline.